Blood, Bone Marrow Aspirate, Tissue

Whole blood (EDTA anti-coagulated; 6 mL pink top tube) or bone marrow aspirate (EDTA anti-coagulated; pink or lavender top tube) or tissue formalin fixed and paraffin embedded.

Tumor specimens containing less than 20% tumor cells may be unacceptable.

Store and send whole blood refrigerated. DO NOT CENTRIFUGE.

Testing is batched.

7-10 days upon receipt in laboratory

Testing is used for identification and characterization of lymphoid and myeloid malignancies as defined by the World Health Organization (WHO) 2017 Classification of Tumors of Hematopoietic and Lymphoid Tissues. It involves RNA next generation sequencing (NGS) using Anchored Multiplex Amplification and NGS of 42 target genes.

This assay is used to detect these alternative RNA fusions and variants in the following genes: ABL1, ABL2, BLNK, CBFB, CBL, CCND2, CRLF2, CSF1R, DGKH, DNTT, DUSP22, EPOR, ETV6, FGFR1, FLT3, IKZF1, IL2RB, IRF4, JAK2, JAK3, KMT2A, LYN, MECOM, MKL1, MYH11, NTRK3, NUP214, NUP98, PBX1, PDGFRA, PDGFRB, PML, PTK2B, RARA, RBM15, RUNX1, RUNX1T1, SH2B3, TCF3, TP63, TSLP, and TYK.

Results Reported: Fusion or variants detected.

Reverse transcription, anchored multiplexed PCR for targeted next-generation sequencing is performed on RNA isolated from bone marrow, blood or formalin-fixed paraffin embedded tissue.

81450